Because large-sized, CD30+, p53+, CMYC+, and EBER+ atypical lymphocytes were identified as poor prognostic factors in RA patients with OIIA TNK-LPDs (p < 0.05), timely treatment with chemotherapy and biologic drugs is necessary for TNK-LPD patients with a progressive clinical course having some of the identified prognostic factors. The gene discussed is TP53; the disease is disseminated peritoneal leiomyomatosis.